Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus: While AT-GAA For Pompe Faces Delay, Troubles Slowly Raise Their Heads
08:57am, Sunday, 15'th Jan 2023
AT-GAA's US approval is still held up by the China delay. Meanwhile, the company faces the risk of appearing overvalued.
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 03'rd Jan 2023
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Mo
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
01:10pm, Friday, 16'th Dec 2022 GlobeNewswire Inc.
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data
Why Is Amicus Therapeutics (FOLD) Up 13.7% Since Last Earnings Report?
04:30pm, Wednesday, 07'th Dec 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus releases phase 3 results in Pompe disease trial
09:14am, Saturday, 19'th Nov 2022
CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe disease. The drug showed it can help people walk and significantly slowed the
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
12:00pm, Tuesday, 15'th Nov 2022 GlobeNewswire Inc.
PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
07:00am, Tuesday, 15'th Nov 2022
PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New Y
Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates
04:15pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates
12:47pm, Tuesday, 08'th Nov 2022
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
05:20pm, Monday, 07'th Nov 2022 GlobeNewswire Inc.
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rar
Amicus Therapeutics (FOLD) Q3 2022 Earnings Call Transcript
01:02pm, Monday, 07'th Nov 2022
Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Bradley Campbell - President, Chief Executive Officer Sébastien Martel - Chie
Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates
09:48am, Monday, 07'th Nov 2022
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 36.84% and 3.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus: Another Day, Another Delay, Pretty Much The Same Silly Reason
02:49am, Wednesday, 02'nd Nov 2022
Amicus approval gets delayed again because the FDA cannot inspect a Chinese facility. China's zero COVID policy is to blame.
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
08:01pm, Friday, 28'th Oct 2022 GlobeNewswire Inc.
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
07:00am, Thursday, 27'th Oct 2022
PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at 8:
